- Home
- TNYA vs LCTX Comparison
TNYA vs LCTX Comparison
Compare TNYA & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TNYA
- LCTX
- Stock Information
- Founded
- TNYA 2016
- LCTX 1990
- Country
- TNYA United States
- LCTX United States
- Employees
- TNYA N/A
- LCTX N/A
- Industry
- TNYA Medicinal Chemicals and Botanical Products
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- TNYA Health Care
- LCTX Health Care
- Exchange
- TNYA Nasdaq
- LCTX Nasdaq
- Market Cap
- TNYA 111.1M
- LCTX 107.3M
- IPO Year
- TNYA 2021
- LCTX N/A
- Fundamental
- Price
- TNYA $0.68
- LCTX $0.99
- Analyst Decision
- TNYA Strong Buy
- LCTX Strong Buy
- Analyst Count
- TNYA 5
- LCTX 5
- Target Price
- TNYA $8.60
- LCTX $4.20
- AVG Volume (30 Days)
- TNYA 2.4M
- LCTX 1.6M
- Earning Date
- TNYA 08-15-2025
- LCTX 08-11-2025
- Dividend Yield
- TNYA N/A
- LCTX N/A
- EPS Growth
- TNYA N/A
- LCTX N/A
- EPS
- TNYA N/A
- LCTX N/A
- Revenue
- TNYA N/A
- LCTX $9,557,000.00
- Revenue This Year
- TNYA N/A
- LCTX N/A
- Revenue Next Year
- TNYA N/A
- LCTX $244.95
- P/E Ratio
- TNYA N/A
- LCTX N/A
- Revenue Growth
- TNYA N/A
- LCTX 19.42
- 52 Week Low
- TNYA $0.36
- LCTX $0.37
- 52 Week High
- TNYA $4.01
- LCTX $1.21
- Technical
- Relative Strength Index (RSI)
- TNYA 43.13
- LCTX 49.72
- Support Level
- TNYA $0.64
- LCTX $0.96
- Resistance Level
- TNYA $0.80
- LCTX $1.09
- Average True Range (ATR)
- TNYA 0.08
- LCTX 0.08
- MACD
- TNYA -0.03
- LCTX -0.02
- Stochastic Oscillator
- TNYA 4.48
- LCTX 21.25
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.